UK pharma and integrated health

The concept of integrated healthcare is not new to the UK, where it has been discussed since the late 1960s. The difference is that now it could really happen. Technology, medicine, regulation and pricing have all evolved to a point where a collaborative, integrated system is not only possible, but desirable – and the data needed for it to become a reality is now available. What does this mean for UK pharmaceutical companies that have historically focused on providing medicines and treatments? On one hand there are calls for them to change – going beyond being simply a supplier of products and moving into the role of partner, sharing risk to drive great health outcomes. On the other hand, the industry’s move into having pipelines that are largely stocked with niche products has created pricing and access questions which are yet to be fully answered. Analysing the current situation and looking for potential routes to the future, this high-level IQVIA/pharmaphorum webinar gave an update on the latest developments and debated how pharma can be a catalyst for change at a time when the NHS is under immense pressure to cut costs and become more efficient. Insight on these pressing issues was provided by a panel of influential healthcare experts that included former secretary of state for health, and NHS Confederation current chairman, Stephen Dorrell. He was joined by: James Roach, director, Accountable Care Partnership, West Essex Health and Care System Andrew Smith, director, Cobic Steve Jowett, country lead for health system engagement, IQVIA Watch the digital debate to learn more about: The evolving NHS and the STP/ICS model of delivery What a collaborative future could look like The role of data in the future NHS Why the STP/ICS model is important for pharma